Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeGamma MedicaGamma Medica Announces Installation at Leading Medical Facility, Mercy Medical Center in Long Island, the First Clinical LumaGEM® Molecular Breast Imaging Technology to New York

Gamma Medica Announces Installation at Leading Medical Facility, Mercy Medical Center in Long Island, the First Clinical LumaGEM® Molecular Breast Imaging Technology to New York

Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Mercy Medical Center a member of Catholic Health Services of Long Island has purchased and installed New York’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening method to mammography, significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

Approximately 50 percent of U.S. women are reported to have dense breast tissue,* however, many women do not realize they have dense breasts or what it means for their increased risk of breast cancer. Because dense breast tissue and cancer both appear white on mammograms, cancer detection through mammography alone is difficult and may lead to false negatives or delayed diagnoses.* Over 40,000 U.S. women die from breast cancer annually, making early detection imperative.*

“We are thrilled to partner with the Mercy Medical Center to provide the women of New York access to state-of-the art MBI technology,” said Philip Croxford, Gamma Medica president and CEO. “Partnering with such a prestigious facility and installing a LumaGEM MBI system provides the opportunity to help women at risk in the New York area.”

“The acquisition of the Molecular Breast Imaging system will better enable the detection of cancer to save lives,” said Mercy’s Executive Vice President and Chief Administrative Officer Ron Steimel. “This is just the latest milestone in Mercy’s longstanding dedication to the fight against cancer.”

While mammograms may fail to detect breast tumors due to tissue density, MBI highlights metabolic activity in these tumors despite breast density, leading to an earlier diagnosis.* A breakthrough retrospective clinical study published in the August issue of the American Journal of Roentgenology confirmed MBI’s high incremental cancer detection rate: MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography.* Approximately 85 percent of these cancers were node negative, meaning they were detected at an earlier stage and presented a better prognosis.*

“Mercy Medical Center is thrilled to add Gamma Medica’s LumaGEM to our suite of leading breast imaging technology,” said Conellia Ha, MD, director of radiology at Mercy. “As a supplement to 3D mammography, MBI will help us detect cancers in dense tissue that may have been missed by mammography alone. We feel confident that LumaGEM will support our mission to provide the best diagnostic care for our patients—the data behind MBI speaks for itself.”

To educate women about breast density and breast cancer screening options, Gamma Medica launched the Be Certain educational campaign, which aims to provide the most accurate information for physicians, patients and caregivers. In addition to education, Gamma Medica is committed to increasing the number of accurate early breast cancer screenings through installations at major facilities like Einstein Medical Center Philadelphia. For more information, visit www.becertain.info.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy